Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes

• Status: Completed
• Trial end date: 2003-04-10
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Asia. The aim of this trial is to compare oral anti-diabetic drug (OAD) combined with insulin vs. insulin alone in subjects with type 2 diabetes not adequately controlled on the current OAD therapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Insulin; Insulin, Globin Zinc; Insulin, Isophane; Isophane insulin, beef; Isophane Insulin, Human; Repaglinide

Criteria

Inclusion Criteria:

• HbA1c between 7.5 % and 13.0% (both inclusive)

• Fasting C-peptide above or equal to 0.33 nmol/l

• BMI (Body Mass Index) between 25 and 32 kg/m2 (both inclusive)

Exclusion Criteria:

• Medical history of treatment with insulin within the last 6 months

• Impaired renal function, defined as serum creatinine above to 1.7 mg/dl (150 µmol/l)